MX2017012319A - Metodos para tratar enfermedad hepática utilizando derivados de acido indano acético. - Google Patents
Metodos para tratar enfermedad hepática utilizando derivados de acido indano acético.Info
- Publication number
- MX2017012319A MX2017012319A MX2017012319A MX2017012319A MX2017012319A MX 2017012319 A MX2017012319 A MX 2017012319A MX 2017012319 A MX2017012319 A MX 2017012319A MX 2017012319 A MX2017012319 A MX 2017012319A MX 2017012319 A MX2017012319 A MX 2017012319A
- Authority
- MX
- Mexico
- Prior art keywords
- liver
- disease
- liver disease
- acetic acid
- acid derivatives
- Prior art date
Links
- BUVKILSTJGGJJN-UHFFFAOYSA-N acetic acid;2,3-dihydro-1h-indene Chemical class CC(O)=O.C1=CC=C2CCCC2=C1 BUVKILSTJGGJJN-UHFFFAOYSA-N 0.000 title abstract 2
- 208000019423 liver disease Diseases 0.000 title abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 208000002467 Acute-On-Chronic Liver Failure Diseases 0.000 abstract 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 abstract 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 abstract 2
- 208000010334 End Stage Liver Disease Diseases 0.000 abstract 2
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 abstract 2
- 208000034613 Isolated polycystic liver disease Diseases 0.000 abstract 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 abstract 2
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 abstract 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 abstract 2
- 208000021033 autosomal dominant polycystic liver disease Diseases 0.000 abstract 2
- 208000024042 cholesterol ester storage disease Diseases 0.000 abstract 2
- 208000013760 cholesteryl ester storage disease Diseases 0.000 abstract 2
- 208000011444 chronic liver failure Diseases 0.000 abstract 2
- 208000007386 hepatic encephalopathy Diseases 0.000 abstract 2
- 210000004185 liver Anatomy 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 201000011374 Alagille syndrome Diseases 0.000 abstract 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 abstract 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 abstract 1
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 108010015181 PPAR delta Proteins 0.000 abstract 1
- 108010016731 PPAR gamma Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 abstract 1
- 208000010157 sclerosing cholangitis Diseases 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención describe el uso de derivados de ácido indano acético los cuales son agonistas delta/gamma de PPAR dual para el tratamiento de enfermedades hepáticas incluyendo una o más de las siguientes: NAFLD (Enfermedad hepática grasa no alcohólica), NASH (Esteatohepatitis No Alcohólica), Enfermedad de Farber, ACLF (Falla Hepátiga Aguda Crónica), CLF (Insuficiencia Hepática Crónica), POLT-HCV-SVR (Trasplante de Hígado Pos-Ortotópico debido a infección por Virus de la Hepatitis C después de la respuesta Viral Sostenida seguido de la Terapia anti-HCV), Síndrome de Alagille, PFIC (Colestasis Intrahepática Familial Progresiva), Colangitis Esclerosa Primaria, ADPCLD (Enfermedad Hepática Policística Dominante Autosomal), tratamiento de pacientes de trasplante de hígado con fibrosis re-establecida, CESD (Enfermedad de Almacenamiento de Éster de Colesterilo), SHTG (Hipertrigliceridemia Severa), HoFH (Hipercolesterolemia Familial Homocigota), HE (Encefalopatía Hepática) o Enfermedad Hepatica Alcohólica..
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562138698P | 2015-03-26 | 2015-03-26 | |
| PCT/US2016/023694 WO2016154258A1 (en) | 2015-03-26 | 2016-03-23 | Methods of treating liver disease using indane acetic acid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017012319A true MX2017012319A (es) | 2018-05-11 |
Family
ID=56977728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012319A MX2017012319A (es) | 2015-03-26 | 2016-03-23 | Metodos para tratar enfermedad hepática utilizando derivados de acido indano acético. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180117013A1 (es) |
| EP (1) | EP3273964A4 (es) |
| JP (1) | JP2018509474A (es) |
| KR (1) | KR20170131644A (es) |
| CN (1) | CN107530352A (es) |
| AU (1) | AU2016235263A1 (es) |
| CA (1) | CA2980296A1 (es) |
| HK (1) | HK1248537A1 (es) |
| IL (1) | IL254653A0 (es) |
| MX (1) | MX2017012319A (es) |
| WO (1) | WO2016154258A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| US12053445B2 (en) | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
| FR3056908B1 (fr) * | 2016-09-30 | 2019-04-19 | Nashpharm | Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie |
| FR3056909B1 (fr) * | 2016-09-30 | 2019-04-19 | Nashpharm | Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| US20180153859A1 (en) * | 2016-12-02 | 2018-06-07 | T3D Therapeutics, Inc. | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype |
| MX382765B (es) * | 2016-12-09 | 2025-03-13 | Zydus Lifesciences Ltd | Tratamiento para la colangitis biliar primaria. |
| SG11201906987RA (en) * | 2017-02-21 | 2019-09-27 | Genfit | Combination of a ppar agonist with a fxr agonist |
| WO2018193007A1 (en) * | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
| WO2022238445A1 (en) * | 2021-05-11 | 2022-11-17 | Genfit | Ppar-agonists for use in the treatment of liver failure |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036237A1 (es) * | 2001-07-27 | 2004-08-25 | Bayer Corp | Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento |
| WO2010028370A1 (en) * | 2008-09-08 | 2010-03-11 | Indiana University Research And Technology Corporation | Use of ppar gamma modulators to treat cystic liver diseases |
| WO2010141696A1 (en) * | 2009-06-04 | 2010-12-09 | Dara Biosciences, Inc. | Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives |
| WO2012074980A2 (en) * | 2010-12-01 | 2012-06-07 | Dara Biosciences, Inc. | Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives |
| US8440797B2 (en) * | 2010-12-06 | 2013-05-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
| JP6865038B2 (ja) * | 2014-04-11 | 2021-04-28 | サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｎａｆｌｄおよびｎａｓｈの治療 |
-
2016
- 2016-03-23 US US15/561,434 patent/US20180117013A1/en not_active Abandoned
- 2016-03-23 AU AU2016235263A patent/AU2016235263A1/en not_active Abandoned
- 2016-03-23 EP EP16769569.1A patent/EP3273964A4/en not_active Withdrawn
- 2016-03-23 JP JP2018501148A patent/JP2018509474A/ja active Pending
- 2016-03-23 CA CA2980296A patent/CA2980296A1/en not_active Abandoned
- 2016-03-23 WO PCT/US2016/023694 patent/WO2016154258A1/en not_active Ceased
- 2016-03-23 HK HK18108174.1A patent/HK1248537A1/zh unknown
- 2016-03-23 MX MX2017012319A patent/MX2017012319A/es unknown
- 2016-03-23 KR KR1020177031085A patent/KR20170131644A/ko not_active Withdrawn
- 2016-03-23 CN CN201680018321.1A patent/CN107530352A/zh active Pending
-
2017
- 2017-09-24 IL IL254653A patent/IL254653A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016154258A1 (en) | 2016-09-29 |
| EP3273964A4 (en) | 2019-01-30 |
| HK1248537A1 (zh) | 2018-10-19 |
| JP2018509474A (ja) | 2018-04-05 |
| CA2980296A1 (en) | 2016-09-29 |
| KR20170131644A (ko) | 2017-11-29 |
| IL254653A0 (en) | 2017-11-30 |
| AU2016235263A1 (en) | 2017-10-12 |
| US20180117013A1 (en) | 2018-05-03 |
| EP3273964A1 (en) | 2018-01-31 |
| CN107530352A (zh) | 2018-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017012319A (es) | Metodos para tratar enfermedad hepática utilizando derivados de acido indano acético. | |
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| JP2018507914A5 (es) | ||
| PE20180690A1 (es) | Composiciones de acido obeticolico y metodos de uso | |
| BR112014010228A2 (pt) | inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática | |
| SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| JP2015517489A5 (es) | ||
| BR112018010650A8 (pt) | pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| PE20180027A1 (es) | Composiciones farmaceuticas para terapia combinada | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| EA201890859A1 (ru) | Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот | |
| NZ724057A (en) | Treatment of intrahepatic cholestatic diseases | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP2016511753A5 (es) | ||
| JP2017508817A5 (es) | ||
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| EA201691555A1 (ru) | Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени | |
| RU2019113150A (ru) | Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения | |
| RU2016127558A (ru) | Стероидное соединение для применения в лечении печеночной энцефалопатии | |
| EA201890862A1 (ru) | Ингибиторы плазменного калликреина человека | |
| WO2016090107A3 (en) | Treatment of hepatitis delta virus infection | |
| RU2019110779A (ru) | Новые схемы введения агонистов fxr |